Lisa E. Davis, PharmD, FCCP, BCPS, BCOP

The campaign for National Stress Awareness Month in April is under way.

This issue of Pharmacy Practice in Focus: Oncology features the publication's first manuscript to undergo peer review.

Ongoing studies utilizing large-scale health databases that incorporate environmental, lifestyle, biological, and phenotypic data may provide insight that leads to better cancer prevention and treatment.

There is much to be learned and progress to be made in all these efforts toward the optimization of tolerability, safety, and efficacy of oncologic therapies.

Psilocybin and other psychedelics hold promise in treating anxiety, depression, substance abuse and addiction, posttraumatic stress disorder, obsessive compulsive disorder, headaches, and chronic pain disorders.

Some common questions for oncology pharmacists are about concurrent use of complementary and alternative medicine supplements and natural products.

Artificial intelligence technology is integrated into the services and products we use every day in our personal and professional lives.

A focus on developing positive connectivity among colleagues may help support hematology/oncology pharmacists’ efforts to advocate for roles that optimize their personal and institutional value.

Oncology pharmacists participate significantly in conversations, research, and publications of that research.

Increasingly, practices will use and evaluate ePROs and DSMSTs in cancer care settings.